

Valbiotis® announces a strategic partnership with Asetys, a complementary health insurance provider and recognized specialist in natural solutions and prevention

La Rochelle, Thursday, November 28 (5:40 P.M. CEST) – Valbiotis® (FR0013254851 – ALVAL, PEA-PME eligible), Valbiotis®, a French scientific research laboratory specialized in the marketing of dietary supplements scientifically proven to prevent metabolic and cardiovascular diseases and maintain optimal daily health, has signed a partnership with Asetys, a complementary health insurance provider specializing in natural therapies. The two companies will be working together to democratize access to natural therapies and maintain better health.

Growth potential

The dietary supplements market is growing rapidly and attracting increasing attention. 61%* of French people consume dietary supplements several times a year, including to prevent certain illnesses. 81%* seek natural products to maintain their health. This new collaboration between Valbiotis® and Asetys meets a strong and growing demand for accessible healthcare products tailored to individual needs. *“Our partnership with Asetys will help us raise awareness of the importance of prevention and holistic care among a wide audience of both patients and therapists. We are uniting our expertise to bring natural health products within reach of everyone,”* said Sébastien Peltier, PhD, CEO and co-founder of Valbiotis®.

Educational workshops and natural solutions for partner therapists and policyholders

As of January 7, 2025, Asetys members will receive **reimbursements for products developed by the Valbiotis® laboratory**, to facilitate access to wellness and prevention solutions. As part of this partnership, Valbiotis® will also be organizing **themed educational workshops** to support Asetys' partner wellness practitioners and therapists as well as its members. These workshops will focus on key health and wellness issues with the aim of raising awareness of the importance of prevention and providing information to encourage a more proactive and informed approach to health. These arenas for discussion are also unique opportunities to collaborate with healthcare professionals and share knowledge and know-how.

**2024 barometer of dietary supplement consumption in France – sample of 1,049 French people aged 18 and over, representative of the population as a whole – February 2024*

About Valbiotis®

Valbiotis® is a French scientific research laboratory specializing in the development and marketing of dietary supplements to prevent and combat the metabolic disorders that cause cardiovascular disease.

Valbiotis® has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of natural dietary supplements designed to reduce the impact of metabolic disorders and minimize cardiovascular risk factors. This approach relies on a multi-target strategy made possible with the use of plant-based resources. In France, Valbiotis® is responsible for marketing its own products. Internationally, its products are the subject of licensing agreements.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers.

Valbiotis® is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis® has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis® is a PEA-SME eligible company.

For more information about Valbiotis®, please visit: www.valbiotis.com

About Asetys

Asetys has been operating as a natural prevention ecosystem since 2015, expanding an innovative complementary health insurance service integrating a professional network of partner wellness practitioners, therapists and laboratories. Asetys chooses its partner laboratories for the excellent quality of their products. For more information, please visit: <https://asetys.fr>

Contacts

Corporate Communication / Valbiotis®

Caroline Lamberti

+33 5 46 28 62 58

caroline.lamberti@valbiotis.com

Financial Communication / Seitosei-Actifin

Marianne Py

+33 1 80 48 25 31

marianne.py@seitosei-actifin.com

Press Relations / Seitosei-Actifin

Michael Scholze

+33 1 56 88 11 14

michael.scholze@seitosei-actifin.com



Name: Valbiotis
ISIN Code: FR0013254851
Ticker Symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.